Metabolic activation of pyrrolizidine alkaloids: Insights into the structural and enzymatic basis

Chemical Research in Toxicology

Volumn 27, Issue 6, 2014, Pages 1030-1039

  Ruan, Jianqing ^a   Yang, Mengbi ^a   Fu, Peter ^b   Ye, Yang ^a,c   Lin, Ge ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HELIOTRINE; INTEGERRIMINE; LASIOCARPINE; LYCOPSAMINE; MONOCROTALINE; PLATYPHYLLINE; PYRROLIZIDINE ALKALOID; RETRONECINE; RETRORSINE; SENECIONINE; SENECIPHYLLINE; SENKIRKINE; UNCLASSIFIED DRUG; CYTOCHROME P450;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; LIVER MICROSOME; LIVER TOXICITY; MALE; MASS SPECTROMETRY; METABOLIC ACTIVATION; MOUSE; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; STEREOSPECIFICITY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM;

ACTIVATION, METABOLIC; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED ICR; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PYRROLIZIDINE ALKALOIDS;

EID: 84902436597     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx500071q     Document Type: Article

References (39)

1. Chung, W. G. and Buhler, D. R. (1994) The effect of spironolactone treatment on the cytochrome P450-mediated metabolism of the pyrrolizidine alkaloid senecionine by hepatic microsomes from rats and guinea pigs Toxicol. Appl. Pharmacol. 127, 314-319 (Pubitemid 24263721)
2. Li, N., Xia, Q., Ruan, J., Fu, P. P., and Lin, G. (2011) Hepatotoxicity and tumorigenicity induced by metabolic activation of pyrrolizidine alkaloids in herbs Curr. Drug Metab. 12, 823-834
3. Fu, P. P., Xia, Q., Lin, G., and Chou, M. W. (2004) Pyrrolizidine alkaloids - genotoxicity, metabolism enzymes, metabolic activation, and mechanisms Drug Metab. Rev. 36, 1-55 (Pubitemid 38387834)
4. Kakar, F., Akbarian, Z., Leslie, T., Mustafa, M. L., Watson, J., van Egmond, H. P., Omar, M. F., and Mofleh, J. (2010) An outbreak of hepatic veno-occlusive disease in Western afghanistan associated with exposure to wheat flour contaminated with pyrrolizidine alkaloids J. Toxicol. 2010, 313280
5. Schneider, J., Tsegaye, Y., Tensae, M., Selassie, S. M., Haile, T., Bane, A., Ali, A., Mesfin, G., and Seboxa, T. (2012) Veno-occlusive liver disease: a case report Ethiop. Med. J. 50 (Suppl 2) 47-51
6. Mattocks, A. R. (1968) Toxicity of pyrrolizidine alkaloids Nature 217, 723-728
7. Ruan, J., Liao, C., Ye, Y., and Lin, G. (2014) Lack of metabolic activation and predominant formation of an excreted metabolite of nontoxic platynecine-type pyrrolizidine alkaloids Chem. Res. Toxicol. 27, 7-16
8. Ma, B., Li, N., and Lin, G. (2012) Importance of metabolic activation study to the safe use of Chinese herbal medicines Curr. Drug Metab. 13, 652-658
9. Rieben, W. K., Jr. and Coulombe, R. A. (2004) DNA cross-linking by dehydromonocrotaline lacks apparent base sequence preference Toxicol. Sci. 82, 497-503 (Pubitemid 39600077)
10. Kim, H. Y., Stermitz, F. R., and Coulombe, R. A. (1995) Pyrrolizidine alkaloid-induced DNA-protein cross-links Carcinogenesis 16, 2691-2697
11. Coulombe, R. A., Drew, G. L., and Stermitz, F. R. (1999) Pyrrolizidine alkaloids crosslink DNA with actin Toxicol. Appl. Pharmacol. 154, 198-202 (Pubitemid 29072502)
12. Kim, H. Y., Stermitz, F. R., Molyneux, R. J., Wilson, D. W., Taylor, D., and Coulombe, R. A. (1993) Structural influences on pyrrolizidine alkaloid-induced cytopathology Toxicol. Appl. Pharmacol. 122, 61-69 (Pubitemid 23289087)
13. Kim, H. Y., Stermitz, F. R., Li, J. K., and Coulombe, R. A. (1999) Comparative DNA cross-linking by activated pyrrolizidine alkaloids Food Chem. Toxicol. 37, 619-625 (Pubitemid 29438562)
14. Hincks, J. R., Kim, H. Y., Segall, H. J., Molyneux, R. J., Stermitz, F. R., and Coulombe, R. A. (1991) DNA cross-linking in mammalian cells by pyrrolizidine alkaloids: structure-activity relationships Toxicol. Appl. Pharmacol. 111, 90-98
15. Lin, G., Cui, Y. Y., and Hawes, E. M. (2000) Characterization of rat liver microsomal metabolites of clivorine, an hepatotoxic otonecine-type pyrrolizidine alkaloid Drug Metab. Dispos. 28, 1475-1483
16. Chung, W. G. and Buhler, D. R. (2004) Differential metabolism of the pyrrolizidine alkaloid, senecionine, in Fischer 344 and Sprague-Dawley rats Arch. Pharm. Res. 27, 547-553 (Pubitemid 43080181)
17. Lin, G., Cui, Y. Y., and Hawes, E. M. (1998) Microsomal formation of a pyrrolic alcohol glutathione conjugate of clivorine. Firm evidence for the formation of a pyrrolic metabolite of an otonecine-type pyrrolizidine alkaloid Drug Metab. Dispos. 26, 181-184 (Pubitemid 28104087)
18. Kasahara, Y., Kiyatake, K., Tatsumi, K., Sugito, K., Kakusaka, I., Yamagata, S., Ohmori, S., Kitada, M., and Kuriyama, T. (1997) Bioactivation of monocrotaline by P-450 3A in rat liver J. Cardiovasc. Pharmacol. 30, 124-129 (Pubitemid 27527384)
19. Miranda, C. L., Reed, R. L., Guengerich, F. P., and Buhler, D. R. (1991) Role of cytochrome P450IIIA4 in the metabolism of the pyrrolizidine alkaloid senecionine in human liver Carcinogenesis 12, 515-519
20. Lin, G., Wang, J. Y., Li, N., Li, M., Gao, H., Ji, Y., Zhang, F., Wang, H., Zhou, Y., Ye, Y., Xu, H. X., and Zheng, J. (2011) Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum J. Hepatol. 54, 666-673
21. Gao, H., Li, N., Wang, J. Y., Zhang, S. C., and Lin, G. (2012) Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids J. Dig. Dis. 13, 33-39
22. U.S. Food and Drug Administration (2001) FDA Advises DietarySupplement Manufacturers to Remove Comfrey Products from the Market,available at http://www.fda.gov/Food/RecallsOutbreaksEmergencies/SafetyAlertsAdvisories/ ucm111219.htm (accessed Jul 6, 2001).
23. U.K. Medicines and Healthcare Products Regulatory Agency (2007) Proposalsto Prohibit the Sale, Supply or Importation ofUnlicensed Medicinal Products for Internal Use Which Contain SenecioSpecies and Proposals to Amend Three Existing Orders, available at http://www.mhra.gov.uk/Publications/ Consultations/Medicinesconsultations/Othermedicinesconsultations/CON2030747 (accessed Mar 27, 2007).
24. Bundesgesundheitsamt (German Federal Health Bureau) (1992) Bekanntmachung über die Zulassung und Registrierung von Arzneimitteln (Abwehr von Arzneimittelrisiken-Stufe II). Bundesanzeiger 111, 4805-4807.
25. International Program on Chemical Safety (1989) Health and Safety Guide No. 26: Pyrrolizidine Alkaloids Health and Safety Guide, World Health Organization, Geneva, Switzerland.
26. Mattocks, A. R. (1968) Chemistry and Toxicology of Pyrrolizidine Alkaloids, Relationships between Structure, Metabolism and Toxicity, pp 320-325, Academic Press, London.
27. Lin, G., Zhou, K. Y., Zhao, X. G., Wang, Z. T., and But, P. P. (1998) Determination of hepatotoxic pyrrolizidine alkaloids by on-line high performance liquid chromatography-mass spectrometry with an electrospray interface Rapid Commun. Mass Spectrom. 12, 1445-1456 (Pubitemid 28485969)
28. Lin, G., Rose, P., Chatson, K. B., Hawes, E. M., Zhao, X. G., and Wang, Z. T. (2000) Characterization of two structural forms of otonecine-type pyrrolizidine alkaloids from Ligularia hodgsonii by NMR spectroscopy J. Nat. Prod. 63, 857-860 (Pubitemid 30452192)
29. Chan, P. C., Haseman, J. K., Prejean, J. D., and Nyska, A. (2003) Toxicity and carcinogenicity of riddelliine in rats and mice Toxicol. Lett. 144, 295-311 (Pubitemid 36966714)
30. Lin, G., Nnane, I. P., and Cheng, T. Y. (1999) The effects of pretreatment with glycyrrhizin and glycyrrhetinic acid on the retrorsine-induced hepatotoxicity in rats Toxicon 37, 1259-1270 (Pubitemid 29236212)
31. Lin, G., Tang, J., Liu, X. Q., Jiang, Y., and Zheng, J. (2007) Deacetylclivorine: a gender-selective metabolite of clivorine formed in female SD rat liver microsomes Drug Metab. Dispos. 35, 607-613 (Pubitemid 46513264)
32. Li, Y. H., Kan, W. L., Li, N., and Lin, G. (2013) Assessment of pyrrolizidine alkaloid-induced toxicity in an in vitro screening model J. Ethnopharmacol. 150, 560-567
33. Mattocks, A. R. (1981) Relation of structural features to pyrrolic metabolites in livers of rats given pyrrolizidine alkaloids and derivatives Chem.-Biol. Interact. 35, 301-310 (Pubitemid 11117483)
34. Xia, Q., Zhao, Y., Von Tungeln, L. S., Doerge, D. R., Lin, G., Cai, L., and Fu, P. P. (2013) Pyrrolizidine alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-induced tumorigenicity Chem. Res. Toxicol. 26, 1384-1396
35. Lin, G., Cui, Y. Y., and Liu, X. Q. (2003) Gender differences in microsomal metabolic activation of hepatotoxic clivorine in rat Chem. Res. Toxicol. 16, 768-774 (Pubitemid 36736608)
36. Xia, Q., Chou, M. W., Kadlubar, F. F., Chan, P. C., and Fu, P. P. (2003) Human liver microsomal metabolism and DNA adduct formation of the tumorigenic pyrrolizidine alkaloid, riddelliine Chem. Res. Toxicol. 16, 66-73 (Pubitemid 36139412)
37. Xia, Q., Chou, M. W., Lin, G., and Fu, P. P. (2004) Metabolic formation of DHP-derived DNA adducts from a representative otonecine type pyrrolizidine alkaloid clivorine and the extract of Ligularia hodgsonnii hook Chem. Res. Toxicol. 17, 702-708 (Pubitemid 38669528)
38. Klein, K. and Zanger, U. M. (2013) Pharmacogenomics of cytochrome P450 3A4: recent progress toward the "missing heritability" problem. Front. Genet. 4, 12, DOI: 10.3389/fgene.2013.00012.
39. Lamba, J. K., Lin, Y. S., Schuetz, E. G., and Thummel, K. E. (2002) Genetic contribution to variable human CYP3A-mediated metabolism Adv. Drug Delivery Rev. 54, 1271-1294 (Pubitemid 35284253)